End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.35 CNY | +0.21% | +3.81% | -1.16% |
Apr. 19 | Autobio Diagnostics' Q1 Profit Jumps 34% | MT |
Apr. 19 | Autobio Diagnostics' 2023 Profit Climbs 4% as Operating Income Stays Flat | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.16% | 4.51B | C | ||
+0.89% | 12.8B | B+ | ||
-10.29% | 7.61B | B- | ||
+1.78% | 5.41B | B | ||
+5.74% | 4.49B | C | ||
-50.70% | 3.29B | D+ | ||
+12.21% | 2.73B | - | - | |
-16.13% | 2.02B | B- | ||
-11.50% | 1.73B | D+ | ||
-5.02% | 1.64B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603658 Stock
- Ratings Autobio Diagnostics Co., Ltd.